These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 38357305)

  • 1. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
    Cui Z; Zhai Z; Xie D; Wang L; Cheng F; Lou S; Zou F; Pan R; Chang S; Yao H; She J; Zhang Y; Yang X
    Front Pharmacol; 2024; 15():1329409. PubMed ID: 38357305
    [No Abstract]   [Full Text] [Related]  

  • 2. The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database.
    Liguori V; Gaio M; Zinzi A; Cagnotta C; Riccardi C; Docimo G; Capuano A
    Biomedicines; 2023 Sep; 11(9):. PubMed ID: 37760979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and treatment patterns of patients with
    Willis C; Au T; Hejazi A; Griswold C; Schabath MB; Thompson J; Malhotra J; Federman N; Ko G; Appukkuttan S; Warnock N; Kong SX; Hocum B; Brixner D; Stenehjem D
    J Manag Care Spec Pharm; 2024 Jul; 30(7):672-683. PubMed ID: 38950155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
    Koehler VF; Achterfeld J; Sandner N; Koch C; Wiegmann JP; Ivanyi P; Käsmann L; Pusch R; Wolf D; Chirica M; Knösel T; Demes MC; Kumbrink J; Vogl TJ; Meyer G; Spitzweg C; Bojunga J; Kroiss M
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):14035-14043. PubMed ID: 37548775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
    Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
    Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial.
    Yılmaz F; Yaşar S; Mandel NM; Kaçan T; Özdemir M; Doğu GG; Şengül N; Meydan N; Başal FB; Tolunay PK; Hamamcı MB; Dinçer OS; Bahçeci A; Özer L; Ajredini M; Kırca Ö; Yersal Ö; Can O; Günaldı M; Demir G; Yalçın Ş
    Target Oncol; 2024 Nov; 19(6):957-964. PubMed ID: 39317891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases.
    Metellus P; Camilla C; Bialecki E; Beaufils N; Vellutini C; Pellegrino E; Tomasini P; Ahluwalia MS; Mansouri A; Nanni I; Ouafik L
    Front Oncol; 2024; 14():1382394. PubMed ID: 39087020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy.
    Vanoli F; Herviou L; Tsuda Y; Sung P; Xie Z; Fishinevich E; Min SS; Mallen W; de Wardin HT; Zhang Y; Jasin M; Antonescu CR
    Oncogenesis; 2023 Feb; 12(1):8. PubMed ID: 36801905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers].
    Fukuda M; Naito Y
    Gan To Kagaku Ryoho; 2022 Oct; 49(10):1048-1050. PubMed ID: 36281593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
    Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
    Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
    Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
    Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions.
    Gouda MA; Thein KZ; Hong DS
    Cancers (Basel); 2024 Oct; 16(19):. PubMed ID: 39410015
    [No Abstract]   [Full Text] [Related]  

  • 14. NTRK fusions in solid tumours: what every pathologist needs to know.
    Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
    Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
    Zhao X; Kotch C; Fox E; Surrey LF; Wertheim GB; Baloch ZW; Lin F; Pillai V; Luo M; Kreiger PA; Pogoriler JE; Linn RL; Russo PA; Santi M; Resnick AC; Storm PB; Hunger SP; Bauer AJ; Li MM
    JCO Precis Oncol; 2021; 1():. PubMed ID: 34036219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
    Blauel ER; Laetsch TW
    Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report.
    Palmerini E; Frega G; Gambarotti M; Frisoni T; Cesari M; Bazzocchi A; Miceli M; Donati DM; Fanti S; Nanni C; Benini S; Longhi A; Paioli A; Marrari A; Hakim R; Righi A; Ibrahim T
    Front Oncol; 2023; 13():1252359. PubMed ID: 37876963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
    Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
    Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
    Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
    Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.